Publications by authors named "Fraser Clift"

Claim this Profile
F
First-Line Use of Higher-Efficacy Disease-Modifying Therapies in Multiple Sclerosis: Canadian Consensus Recommendations.
Mark S Freedman, Fraser Clift, Virginia Devonshire, François Émond, Catherine Larochelle

Can J Neurol Sci· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Overview of Multiple Sclerosis Care in Rural and Urban Newfoundland and Labrador.
Kathleen E Fifield, Neva J Fudge, Shane T Arsenault, Sarah Anthony, Lillian McGrath, Fraser Clift

Can J Neurol Sci· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating T-cell-derived extracellular vesicles as biomarkers of disease activity, axonal injury, and disability in multiple sclerosis.
Jennifer L Zagrodnik, Stephanie N Blandford, Neva J Fudge, Shane T Arsenault, Sarah Anthony, Fraser Clift

Clin Exp Immunol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health Canada Drug Approval Process: A Barrier to Personalized Care in Multiple Sclerosis.
Jiwon Oh, Virender Bhan, Anthony Traboulsee, Sarah A Morrow, Liesly Lee, Fraser Clift

Can J Neurol Sci· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virtual Management of Multiple Sclerosis: Providing Access or Just Phoning it in?
Paul S Giacomini, Jiwon Oh, Sarah A Morrow, Philippe Beauchemin, Fraser Clift

Can J Neurol Sci· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada.
Virender Bhan, Fraser Clift, Moogeh Baharnoori, Kimberly Thomas, Barkha P Patel

J Comp Eff Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translingual neurostimulation combined with physical therapy to improve walking and balance in multiple sclerosis (NeuroMSTraLS): Study protocol for a randomized controlled trial.
Michelle Ploughman, Ganeswara Rao Melam, Syamala Buragadda, Keith R Lohse, Fraser Clift

Contemp Clin Trials· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada.
Moogeh Baharnoori, Virender Bhan, Fraser Clift, Kimberly Thomas, Soukaïna Mouallif

Pharmacoecon Open· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does the use of the Bruton Tyrosine Kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple sclerosis?
Shane Arsenault, Rochelle Y Benoit, Fraser Clift, Craig S Moore

Mult Scler Relat Disord· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of natalizumab in persons with multiple sclerosis: 2022 update.
Sarah A Morrow, Fraser Clift, Virginia Devonshire, Emmanuelle Lapointe, Raphael Schneider

Mult Scler Relat Disord· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Videoconferencing and Multiple Sclerosis Management: Stopgap or Stay Tuned?
Paul S Giacomini, Jiwon Oh, Sarah A Morrow, Philippe Beauchemin, Fraser Clift

Can J Neurol Sci· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-1 receptor antagonist: An exploratory plasma biomarker that correlates with disability and provides pathophysiological insights in relapsing-remitting multiple sclerosis.
Stephanie N Blandford, Dylan A Galloway, John B Williams, Shane Arsenault, Janet Brown, Fraser Clift

Mult Scler Relat Disord· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CV2/CRMP5 antibody-associated hemorrhagic leukoencephalomyelitis treated with steroids, intravenous immunoglobulin, plasmapheresis, and cyclophosphamide.
Laura Chu, Fraser Clift

Mult Scler Relat Disord· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonalcoholic Wernicke's encephalopathy.
Amanda Welsh, Peter Rogers, Fraser Clift

CJEM· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis